Pharmaceuticals, Biotechnology & Life Sciences

FDA approves Afrezza inhaled insulin for kids – MannKind’s breakthrough offers teens a quick, injection‑free diabetes option, boosting control and adherence.

Hyperliquid (HYPE) surges past $67 amid CFTC approval, institutional ETF plans, and buy‑back momentum, positioning it for a $75‑$100 rally and growing DeFi dominance.

Discover how AstraZeneca’s recent FDA approval of Imfinzi for bladder cancer and targeted anselamimab results reshape its oncology strategy and market outlook.

Mirum Pharmaceuticals drives innovation in cholestatic liver disease therapy, boasting a $5.94B market cap and Nasdaq presence while investing heavily in R&D to improve patient outcomes.

Formycon AG’s Q1 2026 results tripled revenue to €13.1 m, powered by FYB203 sales, while tightening EBITDA loss and boosting the biosimilar pipeline for future growth.

Galderma Group AG

NurExone Biologic Inc. tackles patent tightening and rapid Asian approval pathways to protect its spinal‑cord injury treatments, staying ahead in the biotech race.

Halozyme Therapeutics: Explore how its hyaluronidase platform powers next‑gen oncology and drug‑delivery breakthroughs, and why the $8.1 B biotech stock could be poised for growth.

Nutra Pharma Corp’s low $0.0001 stock, $7,160 market cap, and negative P/E signal major financial risks, raising investor doubts about its drug‑innovation plans.

Novavax’s COVID‑19 vaccine strategy hinges on an FDA advisory vote, influencing its future VLP‑based products and investor sentiment.